Case Report on ETV6-NTRK3 Fusion in EGFR-TKI Resistant NSCLC

Figshare hosts a 19.0 KB document detailing a clinical case of osimertinib resistance in non-small cell lung cancer. The report describes a patient with an EGFR exon 19 deletion who acquired an ETV6-NTRK3 fusion and was treated with osimertinib and entrectinib. Authored by Wei Xie, the file was last updated in March 2026.

Use Cases

• Analyze the clinical narrative for details on the EGFR exon 19 deletion and subsequent ETV6-NTRK3 fusion as a resistance mechanism.
• Review the documented patient response to the osimertinib and entrectinib combination therapy regimen.
• Extract information on adverse events, such as hepatorenal failure and sepsis, associated with the combination treatment.

Strengths

• Document is under a permissive CC BY 4.0 license, allowing for broad reuse and sharing.
• Content is highly specific, focusing on a rare ETV6-NTRK3 fusion as a resistance mechanism to EGFR-TKIs.
• The report was updated in March 2026, indicating recent maintenance or review.

Limitations

• The dataset is a single 19.0 KB case report document, offering a very limited scope with no structured tabular data.
• As a narrative case study, it lacks statistical power, generalizability, and quantifiable rows or columns for analysis.
• The primary data format is a DOCX file, which requires specific software for access and is not immediately machine-readable for analysis.

Provenance

Source

Wei Xie via figshare.

Collection Method

Documented clinical case report and literature review.

Time Range

null

Freshness

Last updated 2026-03-23.

Geography

null